AbbVie - United States

AbbVie (NYSE: ABBV), one of the world’s largest pharmaceutical companies, is usually considered a blue chip dividend stock…

SKYRIZI (risankizumab-rzaa) is now approved for patients six years of age and older with moderate-to-severe plaque psoriasis or…

Quick Read KO and ABBV anchor the portfolio at 25% each, rated Very Safe with payout ratios under…

Quick Read NVO sits 44% below its 52-week high with a price-to-free-cash-flow of 5 and a free cash…

Investors seeking reliable dividends and healthcare exposure often find themselves choosing between AbbVie (NYSE:ABBV) and Pfizer (NYSE:PFE). Both…

Equity markets have moved in the wrong direction over the past three weeks. They may not rebound and…

Verizon (VZ) yields 5.4% at its current price, paying $0.69 per quarter and offering higher current income for…

AbbVie has a solid business capable of performing well even in bad times. The company has proven that…

One of these pharmaceutical leaders overcame a major obstacle and has a strong outlook. The other is actively…

Skyrizi and Rinvoq sales are pushing AbbVie’s sales higher. UnitedHealth Group raised its full-year guidance and is rebounding…